Child with HIV maintains viral suppression for three years off treatment
Diagnostic challenges with PrEP use during early HIV infection
New approaches for paediatric dosing: abacavir in newborns, doubling dolutegravir with rifampicin
New mothers with HIV gain more weight on dolutegravir than efavirenz
Immune modulator clears pre-cancerous anal lesions
Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta
Yes, the same life expectancy as HIV-negative people, but far fewer years in good health
Unique transgender vulnerabilities require tailored and specific interventions
Taking PrEP during acute HIV infection for more than 2-3 weeks is likely to cause resistance, Thai study finds
